Skip to content

Observation on the Analgesic Effect of Intrathoracic Intercostal Nerve Block with Liposomal Bupivacaine in Patients Undergoing Single-Port Thoracoscopic Surgery

Observation on the Analgesic Effect of Intrathoracic Intercostal Nerve Block with Liposomal Bupivacaine in Patients Undergoing Single-Port Thoracoscopic Surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104552
Enrollment
Unknown
Registered
2025-06-19
Start date
2025-06-22
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

The group of single-port thoracoscopic surgery with intraoperative application of bupivacaine liposome intercostal nerve block:A. Before the operation, the patient completed routine examinations to ru
Single-port thoracoscopic surgery group:A. Before the operation, the patient completed routine examinations to rule out surgical contraindications. After confirming that the patient met the inclusion

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Elective general anesthesia with double-lumen endotracheal intubation for thoracoscopic unilateral lung surgery; 2. Age: 18 - 65 years old; 3. ASA classification: I - III; 4. BMI: 18 - 28 kg/m²; 5. Informed consent obtained from the patient and signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Contraindications for nerve block (infection or tumor at the puncture site; unclear or abnormal anatomical position at the puncture site; presence of coagulation disorders; allergy to local anesthetics, etc.); 2. Intended transfer to ICU after surgery; 3. Severe cardiopulmonary diseases (organic heart disease; severe arrhythmia; cardiac function grade III-IV; acute exacerbation of chronic obstructive pulmonary disease; FEV1 < 30% of predicted value, etc.); 4. Severe liver and kidney dysfunction; 5. Poorly controlled hypertension or diabetes; 6. History of chronic pain or opioid abuse; 7. Mental illness; 8. Illiteracy, language barriers or significant hearing or vision impairment that prevents communication.

Design outcomes

Primary

MeasureTime frame
Postoperative pain assessment;Postoperative patient-controlled intravenous analgesia opioid dosage;

Countries

China

Contacts

Public ContactRen Yijiu

Shanghai Pulmonary Hospital

ryjscott@tongji.edu.cn+86 133 0169 3861

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026